Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Tomas S. Bocanegra"'
Autor:
Robert P. Giugliano, Helen Kastrissios, Tomas S. Bocanegra, Simon Zhou, Michelle Green, Shashank Rohatagi, Indravadan Patel, Timothy J. Carrothers, Bruce E Dornseif, SaeHeum Song, Satoshi Kunitada, Minggao Shi, Jeanne Mendell, Daniel E. Salazar, Elliott M. Antman, Masaya Tachibana
Publikováno v:
Thrombosis and Haemostasis. 107:925-934
SummaryEdoxaban is a novel, orally available, highly specific direct inhibitor of factor Xa and is currently being developed for the treatment and prevention of venous thromboembolism and prevention of stroke and systemic embolism in patients with no
Autor:
Jacques Caldwell, Larry Hancock, Steven Hurley, Shobha Dhadda, Alan J. Kivitz, Tomas S. Bocanegra, Julie Ball, Arthur L. Weaver, Naurang M. Agrawal
Publikováno v:
Clinical Therapeutics. 21:659-674
A 6-week, multicenter, double-masked, placebo-controlled, paralle1-group study compared the upper gastrointestinal (UGI) safety of Arthrotec ® 75 (diclofenac sodium 75 mg-misoprostol 200 μg; G.D. Searle & Co., Skokie, Illinois) administered twice d
Autor:
Jacques Caldwell, F. Gilbert McMahon, Michael E. Kuss, Marshall Sack, Jitendra Ganju, Robert Trapp, William Makarowski, Howard Offenberg, Tomas S. Bocanegra, David Lee, Robert J. Noveck, Bernard R. Rubin, Susan R.N. Rush, David Sikes, James M. Ratliff, Arthur L. Weaver
Publikováno v:
Clinical Therapeutics. 18:114-124
This 6-week, multicenter, double-masked, placebo-controlled study compared the efficacy, tolerability, and safety of the recommended starting dose of oxaprozin (1200 mg/d) and a 1500-mg/d dose of nabumetone in the treatment of patients with moderate-
Autor:
David Sikes, David Lee, Howard Offenberg, Tomas S. Bocanegra, Marshall Sack, William Makarowski, Susan R.N. Rush, Arthur L. Weaver, Robert Trapp, Bernard R. Rubin, F.Gilbert McMahon, Michael E. Kuss, Jitendra Ganju, Jacques Caldwell
Publikováno v:
Clinical Therapeutics. 17:735-745
This multicenter, 6-week, double-blind, placebo-controlled, parallel-group study compared the efficacy and safety of oxaprozin 1200 mg once daily with that of nabumetone 1000 mg once daily in patients with moderate-to-severe osteoarthritis (OA) of th
Autor:
John G. Fort, Sean Z. Zhao, Tomas S. Bocanegra, Michael E. Kuss, Seema D. Dedhiya, Susan M. Rush
Publikováno v:
Clinical therapeutics. 21(1)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for the treatment of signs and symptoms of osteoarthritis (OA). Nabumetone and oxaprozin are 2 of the newer NSAIDs and have been shown to have similar safety and efficacy profiles.
Autor:
Elliott M. Antman, Christian T. Ruff, Robert P. Giugliano, Dan Salazar, James J. Hanyok, Tomas S. Bocanegra, Michele Mercuri, Eugene Braunwald, Indravadan Patel, Minggao Shi, Sharon Crugnale, Carolyn H. McCabe
Publikováno v:
American Heart Journal. 160:635-641.e2
Background Vitamin K antagonists have been the standard oral antithrombotic used for more than a half century for prevention and treatment of thromboembolism. Their limitations include multiple food and drug interactions and need for frequent monitor
Autor:
J. Findlay Walker, Tomas S. Bocanegra, Maureen E. Keegan, Deborah R. Shapiro, Stephen J. Boccuzzi
Publikováno v:
The American journal of cardiology. 68(11)
Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, has been administered to approximately 2,400 patients with primary hypercholesterolemia with a mean follow-up of 1 year in controlled clinical studies and their open extensions
Publikováno v:
Clinical Pharmacology & Therapeutics. 65:129-129
Publikováno v:
Current Medical Research and Opinion. 9:568-577
A 4-week, double-blind, controlled multi-centre study was carried out in 235 patients with active rheumatoid arthritis to compare the efficacy and tolerance of 500 mg or 1000 mg diflunisal per day administered once daily, in the evening, or in divide
Publikováno v:
The American Journal of Medicine. 87:S47-S53
A 12-week, randomized, double-blind, multicenter study was undertaken to compare the efficacy, tolerability, and safety of simvastatin and gemfibrozil in 290 patients with primary hypercholesterolemia. Patients in stratum I (initial low-density lipop